MoneyWorks4Me

Check Before You Invest : Astrazeneca Pharma India Ltd

BSE: 506820 NSE: ASTRAZEN ISIN: INE203A01020
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Astrazeneca Pharma India Ltd belong to?
Astrazeneca Pharma India Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Astrazeneca Pharma India Ltd a good quality company?
Astrazeneca Pharma India Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Astrazeneca Pharma India Ltd undervalued or overvalued?
Astrazeneca Pharma India Ltd appears Fair, as its key valuation ratios are in line with their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios Current 0-year
Historic Median
Price to Earnings - 58.99
Price to Book - 9.12
Price to Sales - 7.37
EV to EBITDA - 37.04
Q.4 Is Astrazeneca Pharma India Ltd a good buy now?
Astrazeneca Pharma India Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

C: How much debt does the business have and is it at a sustainable level?

Q.1 Debt to Equity ratio of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd Debt-to-Equity ratio is 0.00, which is in line with the industry average of , indicating similar to debt levels in the industry.

Q.2 Debt to cash flow from operations of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd Debt to cash flow from operations is 0, which is at a healthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Astrazeneca Pharma India Ltd?

Q.1 Promoter shareholding and pledge status of Astrazeneca Pharma India Ltd?
Promoters hold 75.00% of the Astrazeneca Pharma India Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Astrazeneca Pharma India Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Astrazeneca Pharma India Ltd vs industry peers?
Astrazeneca Pharma India Ltd revenue CAGR is %, compared to the industry median CAGR of 0.00%, indicating stable growth and maintaining its market share.
Profit Metrics
Current Level 0-year
Industry Median
Revenue Growth (%) - 0
Gross Profit Growth (%) - 9.8
Operating Profit Growth (%) - 7.9
Net Profit Growth (%) - 8.1
Operating Efficiency
Current Level 0-year
Industry Median
Asset Turnover (x) - 0.93
ROE (%) - 9.58
ROCE (%) - 12.24
Cash Conversion Cycle (days) - 64

Valuation & price assessment

Q.1 Stock return of Astrazeneca Pharma India Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 21.1% based on the current price.
9Y 5Y 3Y 1Y
Share Price
CAGR
21.1% 16.7% 15.8% -24.6%
Q.2 Valuation ratios of Astrazeneca Pharma India Ltd vs historical?
The current P/E ratio of 0 is lower than its historical median of 58.99, indicating that the stock is trading below its historical average valuation.
Q.3 How do the current valuation ratios compare with 0-year historical median and industry numbers?
Valuation Ratios Current 0-year
Historic Median
0-year
Industry Median
Price to Earnings - 58.99 -
Price to Book - 9.12 -
Price to Sales - 7.37 -
EV to EBITDA - 37.04 -

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: